TY - JOUR
T1 - Drug-eluting bioresorbable scaffolds in cardiovascular disease, peripheral artery and gastrointestinal fields: a clinical update
AU - Kawashima, Hideyuki
AU - Ono, Masafumi
AU - Kogame, Norihiro
AU - Takahashi, Kuniaki
AU - Chang, Chun-Chin
AU - Hara, Hironori
AU - Gao, Chao
AU - Wang, Rutao
AU - Tomaniak, Mariusz
AU - Modolo, Rodrigo
AU - Wykrzykowska, Joanna J.
AU - de Winter, Robbert J.
AU - Sharif, Faisal
AU - Serruys, Patrick W.
AU - Onuma, Yoshinobu
PY - 2020/7/2
Y1 - 2020/7/2
N2 - Introduction: The technology of bioresorbable scaffold (BRS) spread out after the success of the first-in-man trials of the Absorb. However, the randomized trials demonstrated that major adverse cardiac events and scaffold thrombosis rates of the first-generation Absorb were higher than those of the metallic everolimus-eluting stent. To overcome the shortcoming of the firstly commercialized Absorb, novel technologies have been developed. Areas covered: In this review, we overviewed the field of BRS in the treatment of coronary, peripheral artery and gastrointestinal fields. To date, 10 BRS devices developed by 6 manufacturers have acquired the CE mark in coronary artery disease. Currently 8 BRS are in clinical trial phase, whereas 7 BRS are in preclinical assessment phase. Most new-generation devices have a strut thickness of less than 100 μm. However, late favorable outcome might be achieved not only by device refinement but also by a proper technique of implantation using intra vascular imaging guidance, as well as with a careful patient and lesion selection. Expert opinion: New-generation BRS will be soon tested in the clinical arena to demonstrate improved acute and long-term of safety and efficacy.
AB - Introduction: The technology of bioresorbable scaffold (BRS) spread out after the success of the first-in-man trials of the Absorb. However, the randomized trials demonstrated that major adverse cardiac events and scaffold thrombosis rates of the first-generation Absorb were higher than those of the metallic everolimus-eluting stent. To overcome the shortcoming of the firstly commercialized Absorb, novel technologies have been developed. Areas covered: In this review, we overviewed the field of BRS in the treatment of coronary, peripheral artery and gastrointestinal fields. To date, 10 BRS devices developed by 6 manufacturers have acquired the CE mark in coronary artery disease. Currently 8 BRS are in clinical trial phase, whereas 7 BRS are in preclinical assessment phase. Most new-generation devices have a strut thickness of less than 100 μm. However, late favorable outcome might be achieved not only by device refinement but also by a proper technique of implantation using intra vascular imaging guidance, as well as with a careful patient and lesion selection. Expert opinion: New-generation BRS will be soon tested in the clinical arena to demonstrate improved acute and long-term of safety and efficacy.
KW - Bioresorbable scaffold
KW - CE mark
KW - absorb
KW - new generation scaffold
KW - scaffold thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85086111662&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/17425247.2020.1764932
DO - https://doi.org/10.1080/17425247.2020.1764932
M3 - Review article
C2 - 32456554
SN - 1742-5247
VL - 17
SP - 931
EP - 945
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 7
ER -